Purpose of Review
This report provides an updated overview of pre-clinical and clinical research on the etiology and biological substrates of the cannabis withdrawal syndrome.
Long-term cannabis use is associated with downregulation of type-1 cannabinoid receptors (CB1). Reduced CB1 receptor density is related to increased withdrawal during early abstinence, and the reduction in CB1 receptor density reverses with extended abstinence. Females have been shown to have increased rate and severity of a subset of cannabis withdrawal symptoms compared with men.
Recent studies have extended knowledge of the biological processes and individual difference variables that influence cannabis withdrawal. However, caveats include small sample sizes in clinical studies, participant samples that are predominantly male, and limited examinations of endocannabinoids, enzymes that degrade endocannabinoids, negative allosteric modulators, and other neurobiological systems that may directly impact cannabis withdrawal symptom expression.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance
Compton WM, Han B, Jones CM, Blanco C, Hughes A. Marijuana use and use disorders in the USA, 2002–14: analysis of annual cross-sectional surveys. Lancet Psychiatry. 2016;3(10):954–64.
Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry. 2015;72(12):1235–42.
Allsop DJ, Copeland J, Norberg MM, Fu S, Molnar A, Lewis J, et al. Quantifying the clinical significance of cannabis withdrawal. PLoS One. 2012;7(9):1–12.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.
Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004;161(11):1967–77.
Haney M. The marijuana withdrawal syndrome: diagnosis and treatment. Curr Psychiatry Rep. 2005;7(5):360–6.
Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction. 1999;94(9):1311–21.
Chung T, Martin CS, Cornelius JR, Clark DB. Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents. Addiction. 2008;103(5):787–99.
Balter RE, Cooper ZD, Haney M. Novel pharmacologic approaches to treating cannabis use disorder. Curr Addict Rep. 2014;1(2):137–43.
Benyamina A, Lecacheux M, Blecha L, Reynaud M, Lukasiewcz M. Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Rev of Neurother. 2008;8(3):479–91.
Copeland J, Pokorski I. Progress toward pharmacotherapies for cannabis use disorder: an evidence-based review. Subst Abuse Rehabil. 2016;7:41–53.
Gorelick DA. Pharmacological treatment of cannabis-related disorders: a narrative review. Curr Pharm Des. 2016;22(42):6409–19.
Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs. 2009;23(7):543–53.
Fattore L. Considering gender in cannabinoid research: a step toward personalized treatment of marijuana addicts. Drug Test Anal. 2013;5(1):57–61.
Ehlers CL, Gizer IR, Vieten C, Gilder DA, Stouffer GM, Lau P, et al. Cannabis dependence in the San Francisco family study: age of onset of use, DSM-IV symptoms, withdrawal, and heritability. Addict Behav. 2010;35(2):102–10.
Schepis TS, Desai RA, Cavallo DA, Smith AE, McFetridge A, Liss TB, et al. Gender differences in adolescent marijuana use and associated psychosocial characteristics. J Addict Med. 2011;5(1):65–73.
McRae-Clark AL, Baker NL, Gray KM, Killeen TK, Wagner AM, Brady KT, et al. Buspirone treatment of cannabis dependence: a randomized, controlled trial. Drug Alcohol Depend. 2015;156:29–37.
Sherman BJ, Baker NL, McRae-Clark AL. Gender differences in cannabis use disorder treatment: change readiness and taking steps predict worse cannabis outcomes for women. Addict Behav. 2016;60:197–202.
Herrmann ES, Weerts EM, Vandrey R. Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. Exp Clin Psychopharmacol. 2015;23(6):1–14.
Hart-Hargrove LC, Dow-Edwards DL. Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety. Behav Brain Res. 2012;231(1):48–59.
Davis C, Fattore L. Gender differences in cannabis addiction and dependence. In: Campolongo P, Fattore L, editors. Cannabinoid modulation of emotion, memory, and motivation. New York: Springer; 2015. p. 283–325.
Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry. 2006;19(3):233–8.
Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. Addict Sci and Clin Pract. 2007;4(1):4–16.
Smith NT. A review of the published literature into cannabis withdrawal symptoms in human users. Addiction. 2002;97(6):621–32.
Budney AJ, Hughes JR, Moore BA, Novy PL. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry. 2001;58(10):917–24.
Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J Abnorm Psychol. 2003;112(3):393–402.
Haney M, Comer SD, Ward AS, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology. 1999a;141(4):385–94.
Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology. 1999b;141(4):395–404.
Kouri EM, Pope HG Jr. Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol. 2000;8(4):483–92.
Greene MC, Kelly JF. The prevalence of cannabis withdrawal and its influence on adolescents’ treatment response and outcomes: a 12-month prospective investigation. J Addict Med. 2014;8(5):359–67.
Vandrey R, Budney AJ, Kamon JL, Stanger C. Cannabis withdrawal in adolescent treatment seekers. Drug Alcohol Depend. 2005;78(2):205–10.
Davis HP, Smith DC, Morphew JW, Lei X, Zhang S. Cannabis withdrawal, posttreatment abstinence, and days to first cannabis use among emerging adults in substance use treatment: a prospective study. J Drug Issues. 2016;46(1):64–83.
Lee D, Schroeder JR, Karschner EL, Goodwin RS, Hirvonen J, Gorelick DA, et al. Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. Am J Addict. 2014;23:234–42.
Kouri EM, Pope HG, Lukas SE. Changes in aggressive behavior during withdrawal from long-term marijuana use. Psychopharmacology. 1999;143(3):302–8.
Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2014;12.
Buckner JD, Zvolensky MJ, Ecker AH. Cannabis use during a voluntary quit attempt: an analysis from ecological momentary assessment. Drug Alcohol Depend. 2013;132(3):610–6.
Buckner JD, Zvolensky MJ, Crosby RD, Wonderlich SA, Ecker AH, Richter A. Antecedents and consequences of cannabis use among racially diverse cannabis users: an analysis from ecological momentary assessment. Drug Alcohol Depend. 2015;147:20–5.
ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539–48.
Mechoulam R, Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids. 2000;108(1):1–13.
Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998;21(12):521–8.
Di Marzo V, Piscitelli F. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 2015;12(4):692–8.
Lu H, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516–25.
Cooper ZD, Haney M. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol. 2008;13(2):188–95.
Fattore L, Fadda P, Spano MS, Pistis M, Fratta W. Neurobiological mechanisms of cannabinoid addiction. Mol Cell Endocrinol. 2008;286(1):S97–S107.
Iversen L. Cannabis and the brain. Brain. 2003;126(6):1252–70.
Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL, et al. Delta-9-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 2002;948(1):155–8.
Gonzalez S, Cebeira M, Fernandez-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. Pharmacol Biochem Behav. 2005;81(2):300–18.
Lichtman AH, Martin BR. Cannabinoid tolerance and dependence. In: Pertwee RG, editor. Cannabinoids. Berlin: Springer; 2005. p. 691–717.
• Hirvonen J, Goodwin RS, Li C-T, Terry GE, Zoghbi SS, Morse C, et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry. 2012;17(6):642–9. This study was the first investigation to document cannabinoid receptor downregulation in chronic cannabis users compared to a control group of individuals with 10 or fewer instances of lifetime cannabis use
• D’Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T, et al. Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1(1):60–7. This study examined the time course of cannabinoid receptor downregulation as a function of cannabis abstinence and in relation to cannabis withdrawal scores. Receptor availability increased during abstinence, and on the second day of abstinence, withdrawal scores were negatively correlated with receptor availability
Lichtman AH, Martin BR. Marijuana withdrawal syndrome in the animal model. J Clin Pharmacol. 2002;42(S1):20S–7S.
Petrocellis LD, Grazia Cascio M, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol. 2004;141(5):765–74.
Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol. 1993;46(5):791–6.
Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol. 2007;14(12):1347–56.
Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov. 2008;7(5):438–55.
Piomelli D. The endogenous cannabinoid system and the treatment of marijuana dependence. Neuropharmacology. 2004;47(S1):359–67.
Schlosburg JE, Carlson BLA, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, et al. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J. 2009;11(2):342–52.
Falenski KW, Thorpe AJ, Schlosburg JE, Cravatt BF, Abdullah RA, Smith TH, et al. FAAH −/− mice display differential tolerance, dependence, and cannabinoid receptor adaptation after Δ9-tetrahydrocannabinol and anandamide administration. Neuropsychopharmacology. 2010;35(8):1775–87.
D’Souza DC, Creatura G, Cortes-Briones J, Thurnauer H, Bluez G, Deaso E, et al. FAAH inhibitor treatment for cannabis dependence. Paper presented at: ACNP 2015. 54th annual meeting of the American College of Neuropsychopharmacology; 2015 Dec 6–10; Hollywood, FL.
Fattore L, Melis M, Fadda P, Pistis M, Fratta W. The endocannabinoid system and nondrug rewarding behaviors. Exp Neurol. 2010;224(1):23–36.
Volkow ND, Hampson AJ, Baler RD. Don’t worry be happy: endocannabinoids and cannabis at the intersection of stress and reward. Annu Rev Pharmacol Toxicol. 2017;57(1):285–308.
Cooper ZD, Haney M. Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend. 2014;136:85–91.
Fogel JS, Kelly TH, Westgate PM, Lile JA. Sex differences in the subjective effects of oral Δ9-THC in cannabis users. Pharmacol Biochem Behav. 2017;152:44–51.
Craft RM, Wakley AA, Tsutsui KT, Laggart JD. Sex differences in CB1 vs. CB2 receptor-selective antagonism of antinociception produced by delta-9-THC and CP55,490 in the rat. J Pharmacol Exp Ther. 2012;340(3):787–800.
Craft RM, Marusich JA, Wiley JL. Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci. 2013;92(8):476–81.
Wakely AA, Wiley JL, Craft RM. Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat. Drug Alcohol Depend. 2014;143:22–8.
Wiley J. Sex-dependent effects of delta(9)-tetrahydrocannibinol on locomotor activity in mice. Neurosci Lett. 2003;352(2):77–80.
Khan SS, Secades-Villa R, Okuda M, Wang S, Perez-Fuentes G, Kerridge BT, et al. Gender differences in cannabis use disorders: results from the National Epidemiological Survey of alcohol and related conditions. Drug Alcohol Depend. 2013;130:101–8.
Panlilio LV, Justinova Z, Trigo JM, Le Foll B. Screening medications for cannabis use disorder. Int Rev Neurobiol. 2016;126:87–120.
Marusich JA, Lefever TW, Antonazzo KR, Craft RM, Wiley JL. Evaluation of sex differences in cannabinoid dependence. Drug Alcohol Depend. 2014;137:20–8.
Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC, et al. Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal. Am J Drug Alcohol Abuse. 2010;36(6):311–9.
Clayton HA, Collins FS. NIH to balance sex in cell and animal studies. Nature. 2014;509(7500):282–3.
Fattore L, Spano MS, Altea S, Fadda P, Fratta W. Drug- and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: influence of ovarian hormones. Br J Pharmacol. 2010;160(3):724–35.
Scherma M, Muntoni AL, Melis M, Fattore L, Fadda P, Fratta W, et al. Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. Psychopharmacology. 2016;233(10):1765–77.
Cohn AM, Johnson AL, Rath JM, Villanti AC. Patterns of the co-use of alcohol, marijuana, and emerging tobacco products in a national sample of young adults. Am J Addict. 2016;25(8):634–40.
Agrawal A, Budney AJ, Lynskey MT. The co-occurring use and misuse of cannabis and tobacco: a review. Addiction. 2012;107(7):1221–33.
Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD, et al. Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry. 2013;73(3):242–8.
Moore BA, Budney AJ. Tobacco smoking in marijuana-dependent outpatients. J Subst Abus. 2001;13(4):583–96.
Peters EN, Budney AJ, Carroll KM. Clinical correlates of co-occurring cannabis and tobacco use: a systematic review. Addiction. 2012;107(8):1404–17.
Conflict of Interest
Dr. Nicolas J. Schlienz, Dr. Alan J. Budney, and Dr. Dustin C. Lee have no conflicts to report. Dr. Ryan Vandrey has served as a consultant or received honoraria from Zynerba Pharmaceuticals, Insys Therapeutics, Battelle Memorial Institute, and CW Hemp.
Human and Animal Rights and Informed Consent
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
This article is part of the Topical Collection on Cannabis
About this article
Cite this article
Schlienz, N.J., Budney, A.J., Lee, D.C. et al. Cannabis Withdrawal: a Review of Neurobiological Mechanisms and Sex Differences. Curr Addict Rep 4, 75–81 (2017). https://doi.org/10.1007/s40429-017-0143-1
- Cannabis use disorder
- Endocannabinoid system